| [1］ Siegel R, Ward E, Brawley O, et al. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths[J]. CA Cancer J Clin, 2011, 61: 212-236. [2］ Chene G, Rahimi K, Mes-Masson AM, et al. Surgical implications of the potential new tubal pathway for ovarian carcinogenesis[J]. J Minim Invasive Gynecol, 2013, 20: 153-159. [3］ Mehrad M, Ning G, Chen EY, et al. A pathologist's road map to benign, precancerous, and malignant intraepithelial proliferations in the Fallopian tube[J]. Adv Anat Pathol, 2010, 17: 293-302. [4］ Kuhn E, Kurman RJ, Vang R, et al. TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma-evidence supporting the clonal relationship of the two lesions[J]. J Pathol, 2012, 226: 421-426. [5］ Salvador S, Rempel A, Soslow RA, et al. Chromosomal instability in fallopian tube precursor lesions of serous carcinoma and frequent monoclonality of synchronous ovarian and fallopian tube mucosal serous carcinoma[J]. Gynecol Oncol, 2008, 110: 408-417. [6］ Sehdev AS, Kurman RJ, Kuhn E, et al. Serous tubal intraepithelial carcinoma upregulates markers associated with high-grade serous carcinomas including RSF-1 (HBXAP), Cyclin E and fatty acid synthase[J]. Mod Pathol, 2010, 23: 844-855. [7］ Karst AM, Levanon K, Duraisamy S, et al. Stathmin 1, a marker of PI3K pathway activation and regulator of microtubule dynamics, is expressed in early pelvic serous carcinomas[J]. Gynecol Oncol, 2011, 123: 5-12. [8］ Kuhn E, Kurman RJ, Soslow RA, et al. The diagnostic and biological implications of Laminin expression in serous tubal intraepithelial carcinoma[J]. Am J Surg Pathol, 2012, 36: 1826-1834. [9］ Kuhn E, Meeker A,Wang TL, et al. Shortened telomeres in serous tubal intraepithelial carcinoma: an early event in ovarian high-grade serous carcinogenesis[J]. Am J Surg Pathol, 2010, 34: 829-836. [10］ Kim J, Coffey DM, Creighton CJ, et al. High-grade serous ovarian cancer arises from fallopian tube in a mouse model[J]. Proc Natl Acad Sci USA, 2012, 109: 3921-3926. [11］ Leblanc E, Narducci F, Farre I, et al. Radical fimbriectomy: a reasonable temporary risk-reducing surgery for selected women with a germ line mutation of BRCA1 or 2 genes? Rationale and preliminary development[J]. Gynecol Oncol, 2011, 121: 472-476. [12］ Parker WH. Bilateral oophorectomy versus ovarian conservation: effects on long-term women's heath[J]. J Minim Invasive Gynecol, 2010, 17: 161-166. [13］ Parker WH, Broder MS, Chang E. Ovarian conservation at the time of hysterectomy and long-term health outcomes in the Nurses' Health Study[J]. Obstet Gynecol, 2009, 113: 1027-1037. [14］ Cibula D,Widschwendter M, Majek O, et al. Tubal ligation and the risk of ovarian cancer: review and meta-analysis[J]. Hum Reprod Update, 2011, 17: 55-67. [15］ Manchanda R, Drapkin R, Jacobs I, et al. The role of peritoneal cytology at risk-reducing salpingo-oophorectomy (RRSO) in women at increased risk of familial ovarian/tubal cancer[J]. Gynecol Oncol, 2012, 124: 185-191. [16］ Tone AA, Salvador S, Finlayson SJ, et al. The role of the fallopian tube in ovarian cancer[J]. Clin Adv Hematol Oncol, 2012, 10: 296-306. [17］ Struewing JP, Watson P, Easton DF, et al. Prophylactic oophorectomy in inherited breast/ovarian cancer family[J]. J Natl Cancer Inst Monogr, 1995, 17: 33-35. [18］ Cass I, Walts A, Karlan BY. Does risk-reducing bilateral salpingo-oophorectomy leave behind residual tube?[J]. Gynecol Oncol, 2010, 117: 27-31. [19］ Gerritzen LH, Grefte JM, Hoogerbrugge N, et al. A substantial part of the fallopian tube is left after standard prophylactic bilateral salpingo-oophorectomy[J]. Int J Gynecol Cancer, 2006, 16: 1940-1944. |
